Table 7.
Phase 1b GO30140 study (arm F): objective response [modified from 37]
IRF RECIST v1.1 |
||
---|---|---|
Atezo + Beva (n = 60) | Atezo (n = 59) | |
Confirmed ORR | 12 (20%) (11–32) | 10 (17%) (8–29) |
CR | 1 (2%) | 3 (5%) |
PR | 11 (18%) | 7 (12%) |
SD | 28 (47%) | 19 (32%) |
Non-CR/non-PD | 0 | 1 (2%) |
PD | 17 (28%) | 25 (42%) |
DCR | 40 (67%) | 29 (49%) |
Median DOR, months | NE (NE) | NE (3.7 to NE) |
Median duration of follow-up: 6.6 months. Figures are presented as n (%) or n (%) (95% CI). IRF, independent review facility; Atezo, atezolizumab; Beva, bevacizumab; ORR, objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate; DOR, duration of response; NE, not estimable.